#United States #Boulder #Enliven Therapeutics #Richard Fair #Nasdaq Stock Options

Enliven Therapeutics Completes Grant of Inducement Stock Options

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Boulder, Colorado, announced a significant milestone on December 11, 2025. The company has granted a stock option as an inducement to Richard Fair, who recently took on the role of President and Chief Executive Officer, also becoming a member of the board of directors.

The stock option encompasses 875,000 shares of Enliven's common stock, priced at an exercise rate of $18.77 per share. This price is equivalent to the closing share price on the grant date, ensuring alignment with the company's current market valuation. A notable aspect of this inducement grant is its vesting schedule. Initially, 25% of the shares will become vested on the one-year anniversary of the date of issue, with the remainder vesting monthly thereafter, subject to Mr. Fair maintaining his employment with Enliven.

This strategic decision is part of Enliven's broader commitment to attract and retain top talent in the competitive field of biopharmaceuticals. The grant is contingent upon the terms outlined in the 2025 Inducement Equity Incentive Plan, supporting Nasdaq's listing rules, specifically Rule 5635(c)(4), which allows for such inducements to ensure effective employment decisions aligned with shareholder interests.

About Enliven Therapeutics

Enliven Therapeutics is dedicated to the discovery and development of innovative small molecule therapeutics. With a focus on precision oncology, the company aims to address pressing medical needs through cutting-edge research and development practices. By leveraging insights into clinically validated biological targets alongside unique chemical approaches, Enliven strives to create therapies that not only enhance survival rates but also improve the quality of life for patients.

As Enliven moves forward under the leadership of Richard Fair, it is poised to navigate the complexities of the biopharmaceutical landscape effectively, fostering sustainable growth and continued innovation in medicinal therapies. The company's principles are rooted in a profound commitment to helping people not just live longer, but live better.

The strategic choice to grant these inducement options exemplifies Enliven's approach to fostering a culture of motivation and engagement among its leadership. It reinforces the company’s intention to align executive incentives with company performance, ultimately benefiting shareholders and stakeholders alike.

With this latest development, Enliven Therapeutics is taking vital steps not only in governance but also in cultivating a robust framework for future growth. By prioritizing leadership and talent retention through innovative compensation strategies, Enliven sets a solid foundation for its journey in aiding the sick with groundbreaking therapeutics and addressing unmet health needs around the world.